|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.||Founder, Chairman & CEO||5,32M||56,15M||1955|
|Mr. Michael I. Benkowitz||President & COO||2,83M||7,83M||1972|
|Mr. James C. Edgemond||CFO & Treasurer||2,01M||1,49M||1968|
|Mr. Paul A. Mahon J.D.||Executive VP, General Counsel & Corporate Secretary||2,31M||13,2M||1964|
|Mr. Dewey Steadman C.F.A.||Head of Investor Relations||N/D||N/D||N/D|
|Ms. Holly Hobson||Associate Vice President of Human Resources||N/D||N/D||N/D|
|Kevin T. Gray||Senior Vice President of Strategic Operations & Logistics||N/D||N/D||N/D|
|Mr. Patrick Poisson||Executive VP of Technical Operations||N/D||N/D||1968|
|Dr. Leigh Peterson||Senior Vice President of Product Development||N/D||N/D||N/D|
|Mr. Gil Golden||Senior VP & Chief Medical Officer||N/D||N/D||N/D|
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
L'ISS Governance QualityScore di United Therapeutics Corporation al 1 dicembre 2023 è 2. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 5; diritti degli azionisti: 3; retribuzione: 3.